Breast Cancer Treatment Based on Organ-like Culture

Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03925233

Enrollment

300

Registered

2019-04-24

Start date

2019-01-02

Completion date

2021-12-15

Last updated

2019-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Organoids

Keywords

Drug sensitivity experiment, Resistance mechanism research

Brief summary

Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.

Interventions

DRUGToremifene citrate

Toremifene citrate tablets

DRUGTrastuzumab

Trastuzumab Injection

DRUGDoxorubicin Hydrochloride

Doxorubicin Hydrochloride Injection

DRUGEpirubicin hydrochloride

Epirubicin hydrochloride injection

DRUGFluorouracil

Fluorouracil injection

DRUGPaclitaxel

Paclitaxel injection

DRUGGemcitabine

Gemcitabine injection

DRUGCisplatin

Cisplatin injection

DRUGRecombinant Human Endostatin

Recombinant Human Endostatin Injection

DRUGPirarubicin hydrochloride

Pirarubicin hydrochloride injection

DRUGPyrrolidine

Pyrrolidine tablets

DRUGIxabepilone

Ixapilone Injection

DRUGTamoxifen citrate

Tamoxifen citrate tablets

DRUGVinorelbine tartrate

Vinorelbine tartrate injection

DRUGCarboplatin

Carboplatin injection

DRUGMethotrexate

Methotrexate injection

DRUGEribulin mesylate

Eribulin mesylate injection

DRUGAnastrozole

Anastrozole tablets

DRUGLetrozole

Letrozole tablets

DRUGExemestane

Exemestane tablets

DRUGFulvestrant

Fulvestrant injection

DRUGOlaparib

Olapani pill

DRUGBevacizumab

Bevacizumab injection

DRUGApatinib mesylate

Apatinib mesylate tablets

DRUGPattozumab

Pattozumab injection

DRUGCapecitabine

Capecitabine tablets

DRUGEar particles

Ear particles

DRUGAidi Injection

Aidi Injection

DRUGCyclophosphamide

Cyclophosphamide injection

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form

Exclusion criteria

Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study. Other investigators believe that patients who are not suitable for this study group

Design outcomes

Primary

Measure	Time frame	Description
Detection of cell viability	8 weeks before neoadjuvant chemotherapy	1\. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration.

Secondary

Measure	Time frame	Description
Detection of in vitro model drug sensitivity	8 weeks before neoadjuvant chemotherapy	2\. In vitro model drug sensitivity: sensitive and insensitive
Clinical efficacy assessment according to RECIST criteria	8 weeks before neoadjuvant chemotherapy	Clinical efficacy evaluation according to RECIST criteria: imaging ultrasonography, histological pathology.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026